INS and Hypoglycemia: The primary objective of the Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/ml in Subjects with Type 2 Diabetes Mellitus Inadequately Treated with Basal Insulin and Oral Antidiabetic Drugs (CONCLUDE), a randomised head-to-head clinical trial, was to investigate the effect of insulin degludec 200 U/ml (degludec U200) and glargine U300 on hypoglycaemia in insulin-treated individuals with type 2 diabetes.